Recent updates from Rocket Pharmaceuticals include reporting second-quarter financial results featuring a net income boost driven by a $180 million gross proceeds sale of its Rare Pediatric Disease Priority Review Voucher (PRV), extending its projected cash runway into the second quarter of 2028. Operationally, the company cleared initial safety observations for its Danon disease gene therapy trial under a modified pivotal protocol.